BRIEF—Sarepta lures Biogen exec to CMO post

US biotech company Sarepta Therapeutics has announced the appointment of Gilmore O’Neill as its chief medical officer.

Dr O’Neill will lead all clinical development, medical affairs, pharmacovigilance, and regulatory affairs.

Dr O’Neill joins Sarepta from Biogen, where he held leadership roles of increasing responsibility over a 15-year period in research and development, most recently as senior vice president responsible for all late-stage clinical development.

During his tenure, Dr O’Neill oversaw development programs for Alzheimer’s disease, movement disorders, acute neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy, and rare diseases. He played a leadership role in seeking, receiving and maintaining global marketing approvals for Biogen’s new products.